TIDMSBI
RNS Number : 5564Y
SourceBio International PLC
14 May 2021
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Po sting of Annual Report and Accounts
and Notice of Annual General Meeting
SourceBio International plc (AIM: SBI), a leading international
provider of integrated state-of-the-art laboratory services and
products , c onfirms that the Annual Report and Accounts for the
year ended 31 December 2020 ("2020 Annual Report") and the Notice
of the 2021 Annual General Meeting ("AGM") have now been published
on the Company's website at: https://www.sourcebiointernational.com
(under Investor Relations, General Meetings section).
The 2020 Annual Report, and the Notice of AGM, which includes
details of voting by proxy, will be posted to shareholders who have
not consented to receive electronic communications.
The AGM is to be held on 14 June 2021 at 1pm at the Company's
offices at 1 Orchard Place, Nottingham Business Park, Nottingham,
NG8 6PX and will consider the resolutions set out in the Notice of
AGM.
Due to the UK Government restrictions on public gatherings and
the overriding health and safety concerns, the Company has decided
to hold the AGM as a closed physical meeting, with the minimum
number of Directors who hold shares to be present, to form the
necessary quorum. Regrettably, other shareholders will not be
permitted to attend the meeting in person.
The Company will provide a facility for shareholders to join the
AGM either online or telephonically via the Investor Meet Company
("IMC") platform and there will be an opportunity for shareholders
to ask questions. In order to facilitate the process, the Directors
would request that shareholders register for the meeting and submit
questions in advance, before 5pm on 10 June 2021. Investors can
sign up for IMC for free and add to meet SourceBio International
via:
https://investormeetcompany.com/sourcebio-international-plc/register-investor
Investors who have already registered for the IMC platform and
added to meet the Company will be automatically invited.
Proxy voting
Shareholders wishing to vote on any of the matters of business
are strongly encouraged to appoint the Chairman of the Meeting as
their proxy. If you attempt to appoint a named individual other
than the Chairman of the Meeting, such individual will not be
permitted to attend the Meeting and you will instead be deemed to
have appointed the Chairman of the Meeting as your proxy.
Shareholders will receive a hard copy form of proxy for the 2021
AGM in the post and may also appoint a proxy by submitting a
completed form of proxy to the Company's registrar online at
sharevote.co.uk. Alternatively, shareholders are able to appoint a
proxy via the CREST system. For your vote to be valid, please
ensure it is received no later than 1pm on 10 June 2021. For more
information on voting by proxy, including electronically or via
CREST, please refer to the Explanatory Notes in the Notice of
AGM.
Shareholders may request additional proxy forms directly from
the Registrars, Equiniti, on Tel: 0371 384 2030 (+44 (0)121 415
7047 if calling from outside the UK). Calls are charged at the
standard geographic rate and will vary by provider. Calls outside
the United Kingdom will be charged at the applicable international
rate. Shareholders wishing to appoint a proxy are strongly
encouraged to appoint the Chairman of the Meeting as their
proxy.
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Adviser and Broker) Tel: 020 3100 2000
Bidhi Bhoma
Richard Lindley
Euan Brown
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502
558 258
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Infectious Disease Testing - a range of COVID-19 testing
services for commercial enterprises, private healthcare groups, NHS
and the DHSC. Utilising multiple technologies (PCR, LamPORE, LAMP,
Lateral Flow, Quantitative Antibody tests and whole genome
sequencing for positive results), SourceBio offers both screening
and gold standard COVID-19 testing and operates under ISO 15189
accreditation required by the DHSC. SourceBio also provides
employee testing solutions to industry, direct to consumer home
test kits (including 'Fit to Fly', 'Test to Release' and '2 & 8
Day International Travel' approved tests) whilst also being the
lead operator on mobile testing unit services to support outbreak
testing for the DHSC, event and venue testing.
-- Healthcare Diagnostics - histopathology and clinical
diagnostic services for the NHS and private healthcare across the
UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSBGGDUSSBDGBX
(END) Dow Jones Newswires
May 14, 2021 02:00 ET (06:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024
